Page 1026 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 3

patients with community-acquired respiratory tract infections. 68. Mariat C, Venet C, Jehl F, et al. Continuous infusion of ceftazi-
Antimicrob Agents Chemother. 2001;45:2793-2797. dime in critically ill patients undergoing continuous venove-
62. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic nous haemodiafiltration: pharmacokinetic evaluation and dose
evaluation of factors associated with the development of bacte- recommendation. Crit Care. 2006;10:R26.
rial resistance in acutely ill patients during therapy. Antimicrob 69. Kuti JL, Nicolau DP. Optimal cefepime and meropenem dosing
Agents Chemother. 1998;42:521-527. for ventilator-associated pneumonia patients with reduced renal
63. Ronco C, Bellomo R, Homel P, et al. Effects of different doses function: an update to our clinical pathway. J Crit Care. 2010;
in continuous veno-venous haemofiltration on outcomes of 25:155-156.
acute renal failure: a prospective randomised trial. Lancet. 70. Pea F, Viale P, Pavan F, et al. Pharmacokinetic considerations for
2000;356:26-30. antimicrobial therapy in patients receiving renal replacement
64. Isla A, Maynar J, Sanchez-Izquierdo JA, et al. Meropenem and therapy. Clin Pharmacokinet. 2007;46:997-1038.
continuous renal replacement therapy: in vitro permeability of 71. Goff DA. Antimicrobial stewardship: bridging the gap between
2 continuous renal replacement therapy membranes and influence quality care and cost. Curr Opin Infect Dis. 2011;24(suppl 1):S11-S20.
of patient renal function on the pharmacokinetics in critically ill 72. Katsios CM, Burry L, Nelson S, et al. An antimicrobial stew-
patients. J Clin Pharmacol. 2005;45:1294-1304. ardship program improves antimicrobial treatment by culture
65. Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and site and the quality of antimicrobial prescribing in critically ill
pharmacodynamics of imipenem during continuous renal patients. Crit Care. 2012;16:R216.
replacement therapy in critically ill patients. Antimicrob Agents 73. Nicasio AM, Eagye KJ, Kuti EL, et al. Length of stay and hospital
Chemother. 2005;49:2421-2428. costs associated with a pharmacodynamic-based clinical pathway
66. Tegeder I, Bremer F, Oelkers R, et al. Pharmacokinetics of for empiric antibiotic choice for ventilator-associated pneumonia.
imipenem-cilastatin in critically ill patients undergoing continu- Pharmacotherapy. 2010;30:453-462.
ous venovenous hemofiltration. Antimicrob Agents Chemother. 74. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases
1997;41:2640-2645. Society of America and the Society for Healthcare Epidemiology
67. Malone RS, Fish DN, Abraham E, et al. Pharmacokinetics of of America guidelines for developing an institutional pro-
cefepime during continuous renal replacement therapy in critically gram to enhance antimicrobial stewardship. Clin Infect Dis.
ill patients. Antimicrob Agents Chemother. 2001;45:3148-3155. 2007;44:159-177.

Section05-O-ref.indd 3 1/20/2015 4:51:15 PM